Supplementary Figure 2C from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Authors :: Ulrich Jäger
Hagop Youssoufian
David T. Weaver
Stephanie Lustgarten
Julio Delgado
Paolo Ghia
Stephan Stilgenbauer
Constantine S. Tam
Zsolt Nagy
Nicole Lamanna
James Essell
Carol Moreno
Marco Montillo
Peter Hillmen
Bryone J. Kuss
Matthew S. Davids
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Figure S2C displays probability of progression-free survival over time in subgroups of patients with and without bulky disease

Tools